{
    "organizations": [],
    "uuid": "8af53e032d81ab768450e113441e12ae0a49a3bf",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-dms-signs-via-its-dms-biotech-unit/brief-dms-signs-via-its-dms-biotech-unit-two-agreements-for-lipofilling-solutions-in-europe-idUSFWN1RU15M",
    "ord_in_thread": 0,
    "title": "BRIEF-DMS Signs Via Its DMS Biotech Unit Two Agreements For Lipofilling Solutions In Europe",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 17 (Reuters) - Diagnostic Medical Systems SA :\n* ANNOUNCES UPDATES ON ITS DMS BIOTECH DIVISION * SIGNATURE VIA DMS BIOTECH OF TWO NEW AGREEMENTS FOR LIPOFILLING SOLUTIONS IN EUROPE\n* FILING OF NEW PATENT FOR PRODUCTION OF ADIPOSE TISSUE CELLS\n* DMS BIOTECH SAYS HAS FINALIZED PROSPECTIVE STUDY ON EVALUATION OF STEMCISâ€™S TECHNOLOGY IN TREATMENT OF CANINE OSTEOARTHRITIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-18T00:10:00.000+03:00",
    "crawled": "2018-04-18T18:16:20.028+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "diagnostic",
        "medical",
        "system",
        "sa",
        "announces",
        "update",
        "dm",
        "biotech",
        "division",
        "signature",
        "via",
        "dm",
        "biotech",
        "two",
        "new",
        "agreement",
        "lipofilling",
        "solution",
        "europe",
        "filing",
        "new",
        "patent",
        "production",
        "adipose",
        "tissue",
        "cell",
        "dm",
        "biotech",
        "say",
        "finalized",
        "prospective",
        "study",
        "evaluation",
        "stemcis",
        "technology",
        "treatment",
        "canine",
        "osteoarthritis",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}